Posted by Michael Wonder on 13 Dec 2018
ICER describes for patients and policy makers why the QALY is considered the best way to reward the care that improves patients’ lives
12 December 2018 - ICER reiterates its commitment to equality and will highlight measures of cost-effectiveness that value any extension of life exactly the same across all diseases, regardless of age, severity of illness, or level of disability.
The ICER has posted a summary of the reasons that the quality-adjusted life year (QALY) is the gold standard for measuring how well a medical treatment improves patients’ lives, and has served as a cornerstone of cost-effectiveness analysis in the U.S. and around the world for more than 30 years.
